Which has better valuation & earnings, ERAS or BCAX?

Erasca is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.95 N/A Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A

Is ERAS or BCAX more profitable?

Erasca's return on equity of -38.43% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% Bicara Therapeutics N/A -41.49% -38.59%

Does the media favor ERAS or BCAX?

In the previous week, Erasca had 5 more articles in the media than Bicara Therapeutics. MarketBeat recorded 13 mentions for Erasca and 8 mentions for Bicara Therapeutics. Erasca's average media sentiment score of 1.19 beat Bicara Therapeutics' score of 1.14 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TVTX or BCAX?

In the previous week, Travere Therapeutics had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 10 mentions for Travere Therapeutics and 8 mentions for Bicara Therapeutics. Travere Therapeutics' average media sentiment score of 1.50 beat Bicara Therapeutics' score of 1.14 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bicara Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCAX or DNTH?

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 8 mentions for Bicara Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.56 beat Bicara Therapeutics' score of 1.14 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor PTCT or BCAX?

In the previous week, PTC Therapeutics had 8 more articles in the media than Bicara Therapeutics. MarketBeat recorded 16 mentions for PTC Therapeutics and 8 mentions for Bicara Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat Bicara Therapeutics' score of 1.14 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bicara Therapeutics (BCAX) Competitors

$23.43 -1.40 (-5.64%)

As of 08/28/2026 04:00 PM Eastern

Compare

BCAX vs. KNSA, ERAS, TVTX, DNTH, and PTCT

Should you buy Bicara Therapeutics stock or one of its competitors? Bicara Therapeutics's main competitors and comparable companies include Kiniksa Pharmaceuticals International (KNSA), Erasca (ERAS), Travere Therapeutics (TVTX), Dianthus Therapeutics (DNTH), and PTC Therapeutics (PTCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bicara Therapeutics compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$840.85M	7.25	$59.01M	$0.97	80.49
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

In the previous week, Bicara Therapeutics had 7 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 8 mentions for Bicara Therapeutics and 1 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.87 beat Bicara Therapeutics' score of 1.14 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Overall Sentiment
Kiniksa Pharmaceuticals International	Very Positive
Bicara Therapeutics	Positive

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus target price of $87.38, suggesting a potential upside of 11.90%. Bicara Therapeutics has a consensus target price of $32.64, suggesting a potential upside of 39.29%. Given Bicara Therapeutics' higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Bicara Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Summary

Kiniksa Pharmaceuticals International beats Bicara Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Bicara Therapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Erasca had 5 more articles in the media than Bicara Therapeutics. MarketBeat recorded 13 mentions for Erasca and 8 mentions for Bicara Therapeutics. Erasca's average media sentiment score of 1.19 beat Bicara Therapeutics' score of 1.14 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market.

Erasca presently has a consensus price target of $22.09, suggesting a potential upside of 22.52%. Bicara Therapeutics has a consensus price target of $32.64, suggesting a potential upside of 39.29%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicara Therapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Erasca's return on equity of -38.43% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Erasca is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Summary

Erasca beats Bicara Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Travere Therapeutics currently has a consensus target price of $61.67, indicating a potential downside of 6.10%. Bicara Therapeutics has a consensus target price of $32.64, indicating a potential upside of 39.29%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bicara Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Travere Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, suggesting that its share price is 175% less volatile than the broader market.

Bicara Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Bicara Therapeutics' return on equity of -41.49% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Travere Therapeutics has higher revenue and earnings than Bicara Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$591.33M	10.47	-$25.55M	-$0.46	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

In the previous week, Travere Therapeutics had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 10 mentions for Travere Therapeutics and 8 mentions for Bicara Therapeutics. Travere Therapeutics' average media sentiment score of 1.50 beat Bicara Therapeutics' score of 1.14 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bicara Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Travere Therapeutics beats Bicara Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Dianthus Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 8 mentions for Bicara Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.56 beat Bicara Therapeutics' score of 1.14 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

47.5% of Dianthus Therapeutics shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bicara Therapeutics has a beta of -0.75, suggesting that its stock price is 175% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Bicara Therapeutics currently has a consensus price target of $32.64, suggesting a potential upside of 39.29%. Dianthus Therapeutics has a consensus price target of $124.27, suggesting a potential upside of 17.42%. Given Bicara Therapeutics' higher probable upside, equities analysts plainly believe Bicara Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Bicara Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Bicara Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A
Dianthus Therapeutics	$1.90M	3,038.79	-$162.34M	-$4.15	N/A

Summary

Dianthus Therapeutics beats Bicara Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Bicara Therapeutics compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Bicara Therapeutics (NASDAQ:BCAX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

PTC Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market.

In the previous week, PTC Therapeutics had 8 more articles in the media than Bicara Therapeutics. MarketBeat recorded 16 mentions for PTC Therapeutics and 8 mentions for Bicara Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat Bicara Therapeutics' score of 1.14 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Bicara Therapeutics' return on equity of -41.49% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
Bicara Therapeutics	N/A	-41.49%	-38.59%

PTC Therapeutics currently has a consensus target price of $98.55, suggesting a potential upside of 40.60%. Bicara Therapeutics has a consensus target price of $32.64, suggesting a potential upside of 39.29%. Given PTC Therapeutics' higher possible upside, research analysts clearly believe PTC Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

PTC Therapeutics has higher revenue and earnings than Bicara Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.38	$682.64M	-$0.58	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Summary

PTC Therapeutics beats Bicara Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAX vs. The Competition

Export

Metric	Bicara Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.55B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-7.56	11.62	273.16	25.45
Price / Sales	N/A	1,295.88	605.00	76.62
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	3.31	16.53	12.98	6.14
Net Income	-$137.95M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-1.97%	-0.31%	0.13%	-0.80%
1 Month Performance	-10.81%	9.80%	7.08%	4.13%
1 Year Performance	96.23%	55.66%	24.67%	15.17%

Bicara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAX Bicara Therapeutics	2.3885 of 5 stars	$23.43 -5.6%	$32.64 +39.3%	+96.2%	$1.55B	N/A	N/A	32
KNSA Kiniksa Pharmaceuticals International	3.8708 of 5 stars	$80.20 +1.0%	$87.38 +8.9%	+133.1%	$6.19B	$677.56M	82.68	220	Positive News
ERAS Erasca	2.5311 of 5 stars	$17.76 +0.9%	$22.09 +24.4%	+1,048.4%	$6.16B	N/A	N/A	120	Positive News
TVTX Travere Therapeutics	1.683 of 5 stars	$67.01 +2.7%	$61.67 -8.0%	+275.3%	$6.15B	$490.73M	N/A	460	News Coverage Positive News
DNTH Dianthus Therapeutics	2.4068 of 5 stars	$112.11 +1.9%	$124.27 +10.8%	+349.0%	$6.02B	$2.04M	N/A	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicara Therapeutics (BCAX) Competitors

BCAX vs. KNSA, ERAS, TVTX, DNTH, and PTCT

How does Bicara Therapeutics compare to Kiniksa Pharmaceuticals International?

Summary

How does Bicara Therapeutics compare to Erasca?

Summary

How does Bicara Therapeutics compare to Travere Therapeutics?

Summary

How does Bicara Therapeutics compare to Dianthus Therapeutics?

Summary

How does Bicara Therapeutics compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicara Therapeutics (BCAX) Competitors

BCAX vs. KNSA, ERAS, TVTX, DNTH, and PTCT

How does Bicara Therapeutics compare to Kiniksa Pharmaceuticals International?

Which has preferable earnings & valuation, KNSA or BCAX?

Does the media prefer KNSA or BCAX?

Do institutionals & insiders have more ownership in KNSA or BCAX?

Which has more volatility and risk, KNSA or BCAX?

Do analysts recommend KNSA or BCAX?

Is KNSA or BCAX more profitable?

Summary

How does Bicara Therapeutics compare to Erasca?

Do insiders and institutionals hold more shares of ERAS or BCAX?

Does the media favor ERAS or BCAX?

Which has more volatility and risk, ERAS or BCAX?

Do analysts prefer ERAS or BCAX?

Is ERAS or BCAX more profitable?

Which has better valuation & earnings, ERAS or BCAX?

Summary

How does Bicara Therapeutics compare to Travere Therapeutics?

Do analysts rate TVTX or BCAX?

Which has more volatility and risk, TVTX or BCAX?

Is TVTX or BCAX more profitable?

Which has preferable valuation and earnings, TVTX or BCAX?

Does the media favor TVTX or BCAX?

Summary

How does Bicara Therapeutics compare to Dianthus Therapeutics?

Does the media favor BCAX or DNTH?

Do insiders and institutionals hold more shares of BCAX or DNTH?

Which has more volatility & risk, BCAX or DNTH?

Do analysts recommend BCAX or DNTH?

Is BCAX or DNTH more profitable?

Which has better valuation and earnings, BCAX or DNTH?

Summary

How does Bicara Therapeutics compare to PTC Therapeutics?

Which has more risk & volatility, PTCT or BCAX?

Does the media favor PTCT or BCAX?

Is PTCT or BCAX more profitable?

Do analysts recommend PTCT or BCAX?

Which has better valuation and earnings, PTCT or BCAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools